Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-63898081 |
| Synonyms | |
| Therapy Description |
JNJ-63898081 is a bispecific antibody that binds to prostate specific membrane antigen (PSMA) and CD3, which potentially activates cytotoxic T-lymphocytes resulting in increased death of PSMA-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-63898081 | JNJ63898081|JNJ 63898081 | CD3 Antibody 119 PSMA Antibody 22 | JNJ-63898081 is a bispecific antibody that binds to prostate specific membrane antigen (PSMA) and CD3, which potentially activates cytotoxic T-lymphocytes resulting in increased death of PSMA-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03926013 | Phase I | JNJ-63898081 | A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors | Completed | USA | CAN | 0 |